The anti-obesity drug 'Rimonabant' is likely to face a ban in India, after studies in Europe found a likelihood of psychiatric side effects upon use of the drug.
The drug, manufactured by the Pharmaceutical Company, Sanofi Aventis was launched in Europe in 2006. Seventeen companies in India produce the generic version of this drug.
Drug Controller General of India (DCGI) Surinder Singh said, "The matter of banning the drug Rimonabant was discussed at the Drug Coordination Committee's meeting held on December 10 and will be discussed at the Drug Technical Advisory Body (DTAB) meeting on Monday."
"We have also communicated the same to all state licensing authorities and they have been asked to make sure that the drug is not produced in the country, he added.
The European drug watchdog had issued a warning to member countries to stop the sale of this drug as quickly as possible.
Explaining that no side effects of this drug was reported in India, Singh said, "However, it would take some time before the issue gets cleared as we have not yet recommended a call-back of the drug."